Arimidex is not an anabolic/androgenic steroid but it is an aromatase
inhibitor. Arimidex should not be confused with estrogen
agonists/antagonists such as Nolvadex or Cytadren, but Arimidex directly
blocks the aromatase enzyme thus preventing the conversion of aromatizable
steroids into estrogen. Arimidex has become a very popular ancillary drug
for prevention of gynocomastia as well as the prevention of adema (bloating)
when associated with the use of aromatizable steroids. The use of Arimidex
also has the capability of preventing the conversion of androstenedione and
possibly aromatizable steroids to estrone and estradiol in peripheral
tissues such as adipose tissue. However, Arimidex can significantly lower
serum estradiol levels significantly and this action may be undesired if a
person is to use moderate to substantial amounts of aromatizable steroids
for a long period of time without taking a break from steroid usage.
Arimidex perturbs circulating levels of estrogens, but no adverse affects
have been known to exist in relation to other endocrine systems,
corticosteroids, or thyroid stimulating hormone (TSH). However, roughly 85%
of Arimidex elimination is through hepatic metabolism, so it is suggested to
monitor liver function if possible, but Arimidex is not known to be very
hepatotoxic. Due to the cost of Arimidex being fairly expensive, many people
will opt to use Nolvadex or even Nolvadex in conjunction with smaller
amounts of Arimidex. The dosage of Arimidex is usually between 0.25 mg/day
to 1.0 mg/day dependant upon the amount of aromatizable steroid usage and/or
the individual’s estrogen sensitivity.
Return to Profiles |